The ongoing phase 2 MIRACLE study (ClinicalTrials.gov identifier: NCT04595370) is evaluating the efficacy, safety, and tolerability of the selective MR modulator AZD9977 along with the SGLT-2 inhibitor dapagliflozin in patients with HF (LVEF < 60%) and CKD. The gene discussed is SLC5A2; the disease is hydrops fetalis.